We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Chesnara Plc | LSE:CSN | London | Ordinary Share | GB00B00FPT80 | ORD 5P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 1.50 | 0.56% | 268.00 | 92,448 | 16:35:14 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 267.50 | 269.50 | 271.50 | 266.00 | 270.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Life Insurance | 584.9M | 18.7M | 0.1239 | 21.71 | 402.29M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:35:14 | UT | 12,420 | 268.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 30/1/2025 | 09:07 | UK RNS | Chesnara PLC Director/PDMR Shareholding |
| 29/1/2025 | 07:00 | UK RNS | Chesnara PLC Directorate Changes |
| 23/12/2024 | 09:48 | ALNC |  Chesnara agrees second Canada Life portfolio acquisition in two years |
| 23/12/2024 | 07:00 | UK RNS | Chesnara PLC Acquisition |
| 12/12/2024 | 12:00 | UK RNS | Chesnara PLC Director/PDMR Shareholding |
| 22/11/2024 | 13:55 | UK RNS | Chesnara PLC Director/PDMR Shareholding |
| 14/11/2024 | 14:06 | UK RNS | Chesnara PLC Director/PDMR Shareholding |
| 29/10/2024 | 07:00 | UK RNS | Chesnara PLC Director/PDMR Shareholding |
| 25/10/2024 | 06:00 | UK RNS | Chesnara PLC Block listing Interim Review |
| 11/9/2024 | 06:00 | UK RNS | Chesnara PLC Director/PDMR Shareholding |
Chesnara (CSN) Share Charts1 Year Chesnara Chart |
|
1 Month Chesnara Chart |
Intraday Chesnara Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 09/1/2025 | 20:31 | Chesnara | 2,535 |
| 19/11/2015 | 12:33 | CHESNERA-Investor's chronicle tip for income seekers. | 13 |
| 23/11/2007 | 16:37 | Chesnara, xd. 01/04/05 fin. div. 7.1p, paid 29/04/05 | 167 |
| 04/10/2005 | 17:38 | A screaming bargain | 3 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2025-01-30 16:35:14 | 268.00 | 12,420 | 33,285.60 | UT |
| 2025-01-30 16:29:00 | 269.00 | 27 | 72.63 | AT |
| 2025-01-30 16:20:56 | 268.00 | 5 | 13.40 | AT |
| 2025-01-30 16:20:37 | 269.00 | 5 | 13.45 | AT |
| 2025-01-30 16:20:32 | 269.00 | 20 | 53.80 | AT |
| Top Posts |
|---|
Posted at 30/1/2025 08:20 by Chesnara Daily Update Chesnara Plc is listed in the Life Insurance sector of the London Stock Exchange with ticker CSN. The last closing price for Chesnara was 266.50p.Chesnara currently has 150,954,119 shares in issue. The market capitalisation of Chesnara is £406,066,580. Chesnara has a price to earnings ratio (PE ratio) of 21.71. This morning CSN shares opened at 270p |
Posted at 09/1/2025 19:43 by 1knocker This has never been a share to hold for long term capital growth, but it used to have a very reliable trading range though, and I used to place buy and sell limit orders accordingly. They generally used to trigger a couple of times a year. All i need to do was consider whether to cancel them temporarily as we approached ex div dates.That trading range seems to be a thing of the past, and has been for quite some time now. I don't take much comfort from solvency ratios. if the bottom drops out of the bond markets and companies like this become forced sellers when there are no buyers they are toast, short of a bail out, however 'safe' they have been assessed to be. I don't understand how it can be possible for them to have balanced their assets and liabilities when interest rates rose so quickly after more than a decade of low and negative rates. Frankly on a 'mark to market' basis, i doubt they have. So if there is a crisis which destroys confidence and turns them into forced sellers they are in trouble. Unless and until that happens, they are fine. I think that is what is impacting the share price. We are walking along the cliff edge, sufficiently far from the edge to be safe from stumbling over the edge, but if there were to be a cliff fall occur under our feet that would be curtains. In my view no business which is based on debt and subject to counterparty risk can ever be safe from systemic failure. Systemic risk is notoriously difficult to gauge. Rather like Assad in Syria, the regime can last for ages, and survive many potentially terminal events, then one day the ground disappears from underfoot and the collapse is as swift and complete as it (or at least its date) was unexpected. I think the most important point is to rcognise that such risk is not much dib=versified by holding a number of companies in the sector. Be careful to make sure that you are comfortable with the complete sector weighting in your portfolio rather than merely the individual company weightings. |
Posted at 24/12/2024 10:01 by tag57 I have a lot more faith in CSN management than the current or last UK Govt!!! |
Posted at 24/12/2024 08:43 by pete160 Egg,CSN appears to have a credible management strategy and is consistently moving forward. There is also the (strong imo) possibility of a bidder approaching at some point. |
Posted at 23/12/2024 21:11 by cerrito I got this from Proactivequote CSN’s latest acquisition from Canada Life UK is small but 'highly attractive' according to analysts at Panmure Liberum. The life and pensions group is acquiring £1.5bn assets under administration across 17,000 unit-linked policies for a total consideration of £2 million. By focusing on unit-linked policies, Chesnara should see “an incredibly fast payback period and uplift to cash generation,” adds the broker, adding to its predictable cash generation, which ultimately supports the uninterrupted dividend growth trajectory. “Moreover, this still leaves management with all the firepower to conduct a larger transaction next year should the opportunity present itself.” “To this end, the new policy administration partnership bodes well for migrating policies at scale and generating further efficiencies over time. Although not a large deal, Panmure Liberum suggests it is one of Chesnara’s most attractive on a purely financial metrics basis. The discount to EcV [economic value] means an immediate uplift of £8 million via a reinsurance agreement, while the deal should generate £8 million of cash over five years. More M&A is likely, adds Panmure, with Chesnara having a liquidity position of £200 million through ready cash and a revolving credit facility. In addition, “assuming management keeps its debt leverage at around 30% of its IFRS capital base”, the broker suggests an acquisition with c£300 million of value could provide for an additional debt capacity of c£100 million. “We get the sense management may be willing to participate in larger M&A than in the recent past, especially if traditional competitors and PE houses are focused elsewhere. “Larger peers are trying to focus on organic new business opportunities, while private equity-backed players now have a higher regulatory hurdle. Management has carried out due diligence on several possible transactions, adds Panmure Liberum, with a strong pipeline for the next 6-12 months for value-enhancing transactions. Regulatory metrics are also strong with a Solvency II coverage ratio of 201% at 1H24 (FY23: 205%), compared to a target range of 140%-160%, which implies excess capital above the top end of the target range of £134 million. “This was partly helped by a well-timed tier 2 debt issuance in 2022 and points to the M&A capacity management has on a standalone basis.” Panmure adds that with £200 million of firepower “We expect management to acquire additional insurance portfolios”. Now is a sensible time to be an acquirer as life insurers continue to battle inflation, legacy systems and operational challenges associated with run-off books, it adds. “We also continue to expect a steady flow of new business, which has historically supported around one-third of the dividend cost. “The move to the new outsourcing policy administration partner SS&C will allow for the migration of future acquisitions at scale and bodes well for efficiency improvements.” In conclusion, Panmure says that Chesnara is underrated given trends currently in the life sector. “With a well-timed Tier 2 debt issue and solid balance sheet, management is well positioned to take advantage of closed Life Insurance consolidation. “The Economic Value (EcV) is not immune to market volatility, but a clear vision and focus on value & dividend enhancing acquisitions and new business gives us confidence the EcV will continue to grow through the cycle.” Currently, Panmure estimates the shares trade on a 23% discount to June’s EcV number of 337p, “Which fails to reflect the growth opportunities, outlook, and realistic value of the business”. In addition, the estimated 2024 dividend yield is an attractive 9.6% and 'likely to continue to grow'. 'Buy' with a target price of 420p is its recommendation. Shares today were unchanged at 258p. The formal transfer via the UK courts of the Canada Life portfolio is scheduled to take place at the end of 2025. |
Posted at 12/12/2024 13:22 by mister md Have had CSN sitting in my portfolio for ages and rarely look at it - just happy with the high dividend yield it provides. The directors seem to be buying up stock too, another 10,000 shares director buy RNS'd today. |
Posted at 10/9/2024 12:26 by paulboz The market often behaves like this with solid results e.g. Tesco and Aviva this year. I expect the share price to increase over the coming weeks and if it doesn't CSN remains a great company for those seeking a relatively safe income. |
Posted at 02/9/2024 10:26 by pete160 For a 400 million sized company, the CSN share price and quoted spread certainly does some weird things, particularly around the open and closing. Quite often, the price acts more AIM than main! |
Posted at 16/7/2024 08:36 by wllmherk Fair enough Jubbers, I guess we all have our own style of investing. I continue to hold and have been adding to my position as CSN has not rallied along with some of my other financial stocks and I can't see any obvious reason for the share price weakness. With a market cap of £380m, a positive set of results announced in March 2024 and a dividend yield of 9.5% I see no reason to sell. Furthermore, I wouldn't be surprised if these get bought out......PHNX perhaps.wllm :) |
Posted at 01/7/2024 13:25 by 1knocker I don't see the election result moving the dial here.The factor depressing the csn SP, and most companies in the financial sector, is the risk from bonds, and the mayhem in valuations and risk/reward of swaps and bond derivatives caused by sharp rises in interest rates after a decade and a half of very negative interest rates . The bond/ interest rate chickens have to come home to roost unless central banks go into sharp reverse on interest rates, and the derivative market is so huge that it is impossible to know how far the shock waves will travel amongst banks and companies in the financial sector with large direct and derivative holdings of 'risk free' government bonds. If the dam breaks CSN and the whole sector is way over valued and will face huge losses and share price falls. If it does not, they are way undervalued and will continue to pay huge dividends, though their SPs will probably not rise significantly until the bond risk ceases to be (or rather ceases to be perceived as) a concern. That's how I read it, anyhow. |
Posted at 08/5/2024 12:42 by 1knocker I think the fall in the share price probably has 2 related causes, first that no one really knows yet what the impact of a sudden reversal of a decade of negative after inflation interest rates will be on its investments (the remarkable feature is how few casualties such a sea change has caused so far), and secondly the CEO has no real track record yet but looks as though he may be more 'adventurous' than his predecessor.Any lurking anxiety that the wheels could fall off is particularly bad for the share price of any financial business, because disaster can strike suddenly and catastrophically. I have nio reason to think that CSN is vulnerable, but nor have I any reason to fear for Legal and Gen, a much bigger outfit, with an apparently very strong balance sheet, highly profitable, and with an share price which has also languished for years as the dividend has steadily risen. The share price weakness has been going on so long that I don't think it can be put down to a big seller in the background. If CSN is sound, this a very extended buying opportunity. If not, its a sell at pretty much any price. I have a significant personal interest in it being the former! |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
